ClinicalTrials.Veeva

Menu

Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status and phase

Completed
Phase 3

Conditions

Prostatitis
Prostatic Hyperplasia

Treatments

Drug: Levofloxacin oral tablets

Study type

Interventional

Funder types

Industry

Identifiers

NCT00169585
LEV102341

Details and patient eligibility

About

Multicentric, national, prospective, parallel group, controlled. The Subjects in every center will be randomized and assigned to the pharmacologic arm or the one with the biochemical monitoring

Enrollment

240 patients

Sex

Male

Ages

45+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Only subjects who meet all of the following criteria will be eligible to participate in this study:

  • Male patients

  • Age ≥ 45 years

  • Suspected presence of prostate inflammatory foci, defined according to the following criteria:

  • PSA ≥ 2.6 ng/mL and age ≥ 50 and < 60 years (or ≥ 45 years if the patient has known family predisposition to carcinoma of the prostate) or,

  • PSA ≥ 4.1 ng/mL and age ≥ 60 and < 75 years, and

  • normal digito-rectal examination (DRE) (see section 5.2), and normal urine test with dipstick and/or microscopy carried out within 5 days of the baseline visit

  • Patients willing and able to provide their written informed consent and to comply with study procedures.

    • Patients with LUTS/BPH on watchful waiting or already under treatment with alpha-blockers or 5-ARI (5-alpha reductase inhibitors) for at least 6 months will also be considered eligible to participate in the study.

Exclusion criteria

Patients who meet any of the following criteria will not be eligible to participate in this study:

  • Diagnosis of NIH class I-III prostatitis or clinical evidence of active acute urinary infection and/or known or suspected active bacterial infection at other sites;
  • Diagnosis of prostate carcinoma (or PIN or ASAPS) or prior radical prostatectomy or radiotherapy or other treatments for prostate cancer;
  • PSA > 20 ng/mL;
  • PSA values (including high values) stable over time;
  • Start of a pharmacological therapy with 5-ARI in subjects with LUTS/BPH;
  • Permanent catheter;
  • Prior treatment (within 4 weeks) with levofloxacin for genital-urinary infections;
  • Known or suspected allergy to levofloxacin, including the excipients contained in the pharmacological preparation and/or confirmed tendency to photosensitivity reactions after fluoroquinolone therapy;
  • Concomitant treatment with drugs not allowed in the study
  • Reluctance to undergo prostate biopsy and/or risk of non-compliance;
  • History or current evidence of alcohol or drug abuse in the last 12 months;
  • History of any conditions that, in the opinion of the investigator, may confound the study results or create additional risks for the patient.
  • Participation in any study of investigational or marketed drugs within 30 days before the baseline visit or during the study.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

19

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems